Erbitux approved as single agent for metastatic colorectal cancer
A supplemental Biologics License Application (sBLA) has been approved for monoclonal antibody cetuximab (Erbitux, ImClone/Bristol-Myers Squibb). The therapy can now be used as a single agent in epidermal growth factor inhibitor (EGFR)-expressing metastatic colorectal cancer (mCRC) in patients who have failed treatment with both irinotecan (Camptosar, Pfizer) and oxaliplatin (Eloxatin, Sanofi-Aventis). The approval was based on results of a large phase III trial that compared cetuximab and best supportive care (BSC) with BSC alone in 572 EGFR-positive patients. According to Bristol-Myers Squibb, cetuximab is the only approved biologic therapy that has demonstrated improved overall survival as a single agent in patients with mCRC. Cetuximab is also approved for treating mCRC in combination with irinotecan and for treatment of certain types of head and neck cancer.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.